Compare LESL & CTXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LESL | CTXR |
|---|---|---|
| Founded | 1963 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.7M | 18.9M |
| IPO Year | 2020 | 2010 |
| Metric | LESL | CTXR |
|---|---|---|
| Price | $3.24 | $0.71 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 6 | 2 |
| Target Price | $2.54 | ★ $6.00 |
| AVG Volume (30 Days) | ★ 2.0M | 957.3K |
| Earning Date | 05-18-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 43.38 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,241,915,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.62 | $147.57 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.27 | $0.57 |
| 52 Week High | $6.92 | $2.38 |
| Indicator | LESL | CTXR |
|---|---|---|
| Relative Strength Index (RSI) | 70.10 | 48.29 |
| Support Level | $0.90 | $0.66 |
| Resistance Level | $3.74 | $0.97 |
| Average True Range (ATR) | 0.54 | 0.05 |
| MACD | 0.14 | 0.00 |
| Stochastic Oscillator | 52.94 | 73.19 |
Leslies Inc is a direct-to-consumer pool and spa care brand offering a comprehensive assortment of products, including chemicals, equipment and parts, cleaning and maintenance equipment, and safety, recreational, and fitness-related products. The company serves residential pool, residential spa, professional pool, and commercial pool consumers and markets its products through over 1,000 company-operated locations in 39 states and e-commerce websites, operating only in the United States. It operates mainly in the pool and spa aftermarket industry and offers regularly purchased, non-discretionary maintenance items, along with installation and repair services for pool and spa equipment.
Citius Pharmaceuticals Inc is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care and distinct prescription products. It aims to provide therapeutic products that address unmet medical needs yet have a lower development risk than is usually associated with new chemical entities. The company's flagship product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein. It operates through a single operating and reportable segment which is focused on developing and commercializing pioneering targeted oncology therapies.